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The  cell  surface  F9  antigens  are  defined  by  the  129/Sv  anti-F9  serum  (1),  a 
syngeneic  antiserum  raised  against  irradiated  cells  of  the  murine  F9  embryonal 
carcinoma  (E.C.) 1 line  (2).  Through  complement-mediated  cytotoxicity or  indirect 
immunofluorescence  (IF)  tests,  the  F9  antigens  appear  to  be  cell  surface  antigens 
characteristic of EC  cells and  their  normal  embryonic  counterpart.  They  are  also 
found on cells of the male germ line (1, 3, 4). 
It has been shown recently (5)  that the antibody response of 129/Sv mice against 
F9 cells is complex; nearly all the cytotoxic activity of the serum is associated with the 
IgM antibodies, whereas the binding of IgM, IgGl, and IgG2a,b anti-F9 antibodies to 
the surface of F9 cells can be revealed by IF. 
We have isolated the anti-F9 IgM, IgG1, and  IgG2a,b antibodies from  the crude 
anti-F9 serum using an affinity chromatography technique  (6). The activities of the 
thus isolated Ig were tested by IF on a  panel of cell types. The results reported in the 
present  paper  suggest  that  the  anti-F9  antibodies  react  with  three  independent 
antigenic determinants. 
Materials  and  Methods 
Sera 
ANTI-~ SEI~.  Anti-F9 sera were raised in syngeneic male 129/Sv mice against irradiated 
(2,000  rad)  cells of the quasi-nullipotent F9,  EC  line, as described earlier (1,  5).  Two  sera 
prepared  independently  (pooled bleedings after the  4th  booster injection of F9 cells) were 
studied and found to display identical properties. They were heat-inactivated (56°C, 30 min), 
centrifuged (10,000 g, 30 min, 4°C), and stored as aliquots at -78°C. 
NORMAL MOUSE SERUM.  Normal  mouse  serum  was  taken  from  male  129/Sv  mice,  heat- 
inactivated, centrifuged, and stored as above. 
RABBIT ANTI-MOUSE  IG.  Rabbit anti-mouse Ig, labeled with fluorescein (RAMIg-FITC) was 
purchased from Institut Pasteur Production, Paris. Before its use, the serum was extensively 
dialyzed and then absorbed with F9, PYS-2, and PCC3/A/1 cells as described (7). All batches 
of RAMIg-FITC used were found to react, in double diffusion tests against purified myeloma 
proteins, with all classes and subclasses of mouse Ig (5). 
Cells.  The cell lines used here have been described elsewhere (Table I) (2, 8-21)i Lympho- 
cytes were prepared from thymuses of 4-wk-old 129/Sv mice as described in (22). 
* Supported by grants from the Centre National de la Recherche Scientifique, the Institut National de 
la Sant~ et de la Recherche M~dicale, the D~l~gation G~n~rale ~ la Recherche Scientifique et Technique, 
The National Institutes of Health, and the Andr~ Meyer Foundation. 
i Abbreviations used in this paper:  DMEM,  Dulbecco's modified Eagle's medium;  E.C., embryonal  carci- 
noma; FCS for fetal calf serum; IF, indirect immunofluorescence; PBS, phosphate-buffered saline; RAMIg- 
FITC, rabbit anti-mouse Ig labeled with fluorescein. 
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TABL~  I 
Description of Cell Lines Used in Thzs Paper 
Refer- 
Cell line  Genetic background  Origin  Cell type  In vivo differentiation  Malignancy* 
ence 
F9-41  129/Sv  Induced OTT6050:~  E.C.§  Endoderm  (rare)  +  2 
PCC4  129/Sv  OTT6050:[:  E.C.  3 germ layers' derivatives  +  8 
PCC4-azaR 1  129/Sv  PCC4  E.C.  3 germ layers' derivatives  +  8 
PCC3  129/Sv  OTT6050~:  E.C.  3 germ layers' derivatives  +  8 
PCC3/A/1  129/Sv  PCC3  E.C.  3 germ layers' derivatives  +  9 
PCC8-S  129T/t win  Spontaneous, testicular  E.C.  3 germ layers' derivatives  +  1[ 
PSA- I  129/Sv  Induced, OTT5868¶  E.C.  3 germ layers' derivatives  I 0 
LT- I  LT  Spontaneous, ovarian  E.C.  None  +  I 1 
C 17S 1  -A  C3H  Induced, C 17* *  E.C.  3 germ layers' derivatives  +  12 
C17S1-lI17  C3H  C17"*  E.C.  3 germ layers' derivatives  +  12 
Tera I  Human  Spontaneous, testicular  NT:~:~  +  13 
PYS-2  129/Sv  OTT6050~c  Parietal endoderm  Parietal yolk sac  ±  14 
3/A/I/D-3  129/Sv  PCC3  Embryonal fibroblast  0  -  15 
3/A/l/D- I  129/Sv  PCC3  Mesenchyme  Bone tissue  +  35 
SVT2  BALB/c  Fibroblast  Fibrosarcoma  +  16 
FI0  BALB/c  ×  I29/Sv  Hybrid  PCC4-azaRi  ×  Fibroblast  Pibrosarcoma  +  17 
SVT2 
PCD3  129/Sv  OTT6050:~  Fibroblast  0  -  18 
PC D2  129/Sv  OTr60505  Myoblast  0  -  19 
TDM 1  129/Sv  PCC3  Trophoblast  Trophoblwstoma  +  20 
Friend  DBA/2  F4N  Erythroid cell  Erythroleukaem ia  +  21 
* Malignancy, determined by injection of 2.5  llf cells into syngeneic mice; +  malignant;  --  nonm~dignant. 
(YFT6050, derived from a  6.5-d-old  129/Sv cmbryu grafted into the testis of an F~ (A/He X  129/Sv) host. 
§ This cell line undergoes differentiation  under in vitro culture conditions. 
¶ OTFS-diS, derived from a  3.5-d-old  129/Sv embryo grafted into the testis of an Fj (A/He ×  129/Sv) host. 
II H. Jakob. Unpublished observations. 
** ('17, derived from a  7.5-d-old C3H emblyo grafted in a C3H host. 
~c:~ NT, not tested. 
Embryos.  The procedures for the preparation and the immunolabeling  of preimplantation 
embryos were essentially as described elsewhere  (7). Blastocyst  inner cell masses were isolated 
following the  technique of Solter and Knowles (23). Most  of the embryos used  here  were 
produced by hormonally primed 4-  to  5-wk-old  129/Sv mice mated with syngeneic males. 
Embryos  from  spontaneously ovulated  females  were  used  occasionally and  gave  identical 
results. 
Fractionation of lmmunoglobulins.  IgM,  IgG1,  and  IgG2a,b  antibodies were  separated  by 
affinity chromatograhy through a column of Protein-A sepharose (Pharmacia Fine Chemicals, 
Div. of Pharmacia Inc., Piscataway, N. J.), following Ey et al. procedure (6). Briefly,  1 ml of 
serum was mixed with  1 ml of 0.1  M  phosphate buffer, pH 8.0, and adjusted to pH 8.0. This 
mixture was then applied onto a column of Protein-A-Sepharose (3 ml) preequilibrated with 
0.1 M phosphate buffer, pH 8.0. The column was washed with the same buffer and the effluent 
(referred  below as IgM) collected. The column was then washed with several volumes of citrate 
buffer 0.1 M, pH 6.0; the eluted material (IgG1) was saved. After extensive washing with the 
same buffer, pH 5.6, the still bound IgG2a and IgG2h were eluted simultaneously  with citrate 
buffer pH 3.0, 0.1  M. The effluent was saved and is referred to below as IgG2a,b. The three 
fractions were neutralized, concentrated through an Amicon PM 10 membrane (Amicon Coo., 
Scientific Systems Div., Lexington, Mass.), adjusted to 4% fetal calf serum (FCS), and dialyzed 
overnight against 100 vol of phosphate-buffered saline (PBS). The separated Ig were stored at 
-78°C as aliquots. To be able to compare the various preparations used, the volume of each 
fraction is referred  to  a  dilution of the  unfractionated serum, i.e.,  when 8  ml of IgM  are 
recovered from 1 ml of crude serum, the IgM preparation is taken as diluted 1/8. 
The purity of each fraction was checked by double diffusion of the separated Ig (~ 1 mg/ml) 
against antibodies raised against purified myeloma proteins (5). Material unbound at pH 8.0 
contained IgM and no contaminating IgG. Because IgA and IgE antibodies are essentially 
unreactive onto F9 cells (5), IgM were not further purified. Material eluted at pH 6.0 reacted 
only with anti-yl chain sera. Material eluted at pH 3.0 reacted with both anti-y2, and anti-y2b 
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Immunofluorescence Test.  All experiments were conducted on suspensions  of living cells using 
the double sandwich technique (22). Washed cells (10  s) were suspended in 50/d of immuno- 
globulin at the appropriate dilution.  After 45 min at 4°C, the unbound Ig were removed by 
three washings  with Dulbecco's modified Eagle's medium (DMEM) containing 4% FCS. The 
washed cells were suspended in a  1/25 dilution of RAMIg-FITC and incubated for 30 min at 
4°C. The cells were then washed three times in DMEM + 4% FCS and examined under a Zeiss 
epi-illumination fluorescent microscope (Carl Zeiss, Inc., New York). Controls, using Ig prepared 
from normal mouse serum or anti-F9 Ig absorbed with  F9 cells, were run  in  parallel. The 
fraction of labeled cells, out of a total of 200 cells examined, was noted. The intensity of the 
immunostaining was scored from 0, no labeling to +++, very intense labeling. 
The  immunofluorescence test  on  preimplantation  embryos was  performed as  described 
previously (7). 
Cytotoxicity Test.  The cytotoxicity test on F9 cells was  performed according to published 
procedures (1). 
Results 
Activity  of IgM, IgGl, and IgG2a,b  Anti-F9 Antibodies on F9 Emb~yonal Carcinoma Cells. 
Fractions containing various classes or subclasses of immunoglobulins were prepared 
from anti-F9 sera, and serotyped as described in Materials and Methods. They proved 
to  have  the  following  properties:  (a)  The  IgM-containing  fraction  had  retained 
cytotoxic activity: 80-100% F9 cells could be killed;  the cytotoxic titer was  1/2,000- 
1/2,400 (compared with, 1/2,000-1/3,200  for the crude serum). 70-90% F9 cells could 
be  labeled  with  a  high  intensity  in  an  IF test  at  the  1/8-1/256  dilutions.  (b)  The 
IgGl-containing fraction did not display any cytotoxic activity, but could label up to 
100% of cells in the 1/2.5-1/20 range of dilutions.  (c) The IgG2a,b anti-F9 antibodies 
were  not  cytotoxic,  but  could  label  up  to  100%  of cells  in  the  1/6-1/48  range of 
dilutions. 
Controls were run with IgM, IgG1, and IgG2a,b antibodies prepared from normal 
mouse serum. These had no activity on F9 cells in either test, at the lowest dilutions 
used (1/10,  1/3, and  1/3, respectively). 
Activity  of IgM, IgG1, and IgG2a, b Anti-F9 Antibodies on a Panel of Cell  Types.  These 
three  preparations  were  tested  by  IF  on  a  variety  of  cell  types:  (a)  embryonal 
carcinoma cells from different, eventually independent, origins, genetic backgrounds, 
and biological characteristics;  (b) differentiated cells, mostly derived from embryonal 
carcinoma cells. 
Activity of IgM anti-F9 antibodies.  The results of this typing are summarized in 
Table II. At the  1/64 dilution,  all E.C. lines were found to react strongly with IgM 
anti-F9 antibodies. The percentage of positive cells, however, varies widely according 
to the lines, some of them  (PCC4-azaR1  and Tera  1, a  human teratoma line)  (13), 
showing  only  15%  of labeled  cells.  The  labeling  is  easily  detectable  even  at  high 
dilutions (1/128 and  1/256), especially on cells from three lines, F9, PSA-1, and LT1 
(a female teratoma line)  (11), which thus appear to be the lines displaying the largest 
amount of IgM binding-antigens. 
In contrast, anti-F9 IgM antibodies, used at the same 1/64 dilution,  did not react 
with differentiated cells. At a lower dilution (1/32), a few positive cells (1-15%) could 
be observed in several cell types with a  variable staining  (+ to +++). The meaning 
of this  positive response,  however, is questionable;  for instance,  absorption  of IgM 
anti-F9 antibodies with PYS-2 cells (diluted  1/16, vol:vol, 1 h, 4°C) did not result in 1500  IDENTIFICATION AND DISTRIBUTION OF F9 ANTIGEN COMPONENTS 
TABLE  II 
Activity of IgM, IgG l, and IgG2a, b Anti-F9 Antibodies on Different Cell Types 
Cell type 
IgM  IgG1  IgG2a,b 
lnten-  Per-  Dilu-  Per-  Dilu-  Per-  Dilu- 
sity  cent  tion  Intensity  cent  tion  Intensity  cent  tion 
Undifferentiated 
F9-41  +++  70  1/64  +++  100  1/10  ++  100  1/12 
PCC4  ++  60  1/64  ++  15  1/10  0  0  1/12 
PCC4-azaR 1  +  15  1/64  0  0  1/10  0  0  1/12 
PCC3  + +  70  1/64  Traces  100  1  / 10  Traces  100  1  / 12 
PCC3/A/1  ++  50  1/64  0  0  1/10  0  0  1/12 
PCC8-S  ++  60  1/64  0  0  1/10  0  0  1/12 
PSA-1  +++  100  1/64  +++  100  1/10  ++  100  1/12 
LT-1  +++  100  1/64  0  0  1/10  0  0  1/12 
C17S1-A  ++  50  1/64  0  0  1/10  0  0  1/12 
C17S1-1117  +++  5  1/64  ++  5  1/10  Traces  4  1/12 
Tera I  +++  15  1/64  +  100  1/10  +  100  1/12 
Differentiated 
PYS-2  +  15  1/32  Traces  100  1/5  0  0  1/6 
PCC3/A/I*  0  0  1/32  0  0  1/5  0  0  1/6 
3/A/I/D-3  0  0  1/32  Traces  100  1/5  0  0  1/6 
3/A/1/D-  1  0  0  1/32  Traces  50  1/5  0  0  1/6 
SVT2  0  0  1/32  0  0  1/5  0  0  1/6 
FI0  +++  1  1/32  0  0  1/5  0  0  1/6 
PCD3  0  0  1/32  +  100  1/5  +  100  1/6 
PCD2  ++  2  1/32  ++  100  1/5  ++  100  1/6 
SV40-PCD2  0  0  1/32  ++  100  1/5  ++  100  1/6 
TDMI  0  0  1/32  0  0  1/5  0  0  1/6 
Friend  +  5  1/32  Traces  100  1/5  0  0  1/6 
Thymocytes  0  0  1/32  0  0  1/5  0  0  1/6 
* HMBA induced differentiated derivative of PCC3/A/1 (24). 
any apparent  decrease of activity of the reagent on F9 cells, although the activity on 
PYS-2 cells had disappeared. 
Activity of IgGl  anti-F9  antibodies.  The  results  are  summarized  in  Table  II. 
Contrasting with the comparatively simple pattern of reactivity of IgM, IgG 1 anti-F9 
antibodies reacted with very different cell types. At the 1/10 dilution, some E.C. lines, 
irrespective of their origin, did not react at all, whereas some of them (F9 and PSA-1) 
had  100%  of  their  cells  reacting  strongly.  Among  differentiated  cell  lines,  only 
mesodermal cell types (18,  19) were brightly labeled. Other differentiated cells tested 
failed to react even at a  lower dilution (1/5).  IgG1  anti-F9 antibodies were absorbed 
with mesodermat cells (vol/vol, 1 h, 4°C) and tested back on F9 cells. This absorption 
did not result in any significant decrease of activity of IgG1 anti-F9 antibodies on F9 
cells. 
Activity of IgG2a,b, anti-F9 antibodies.  The results are summarized in Table II. 
At the  1/12 dilution, the same E.C. cell lines that reacted with IgG1 also reacted with 
IgG2a,b;  the  others  did  not.  Among  differentiated  cells,  again,  only  mesodermal 
derivatives  reacted.  The  other  differentiated  lines  were  negative  even  at  the  1/6 
dilution. IgG2a,b anti-F9 antibodies were absorbed with mesodermal derivatives (vol/ MORELLO,  CONDAMINE,  DELARBRE,  BABINET,  AND  GACHELIN  1501 
vol, diluted 1/6, 1 h, 4°C) and tested back on F9 cells. As for IgG1 anti-F9 antibodies, 
absorption of IgG2 antibodies did not change their activity on F9 cells. 
Activity  of IgM,  IgGl,  and  IgG2a, b  Anti-F9  Antibodies  after  T~ypsinization  of E.C. 
Cells.  F9 and Tera I cell lines were mildly trypsinized (0.5 mg/ml,  10 min, 22°C). 
After such a treatment, ~95% of the cells were alive. 
The trypsinized cells were then assayed in IF test for their ability to bind IgM, 
IgG1, and IgG2a,b anti-F9 antibodies. With both cell lines, no significant decrease in 
the IgM-binding capacity of the cells was observed. In contrast, receptors to IgG 1 and 
IgG2a,b remained barely detectable at the lowest dilution of reagent used (1/10 and 
1/12 for IgG1 and IgG2a,b antibodies, respectively). 
Activity of IgM, IgG1,  and IgG2a, b Antibodies on Preimplantation Embryos.  The normal 
counterpart of embryonal carcinoma cells is to be found in the multipotential cells of 
the early embryos (25).  The F9 antigens have been found on early embryonic cells, 
and their expression during development is well documented (1, 4, 26, 27). The way 
in which the receptors of the main components of the anti-F9 serum are expressed 
during early embryogenesis has therefore been investigated. The results obtained are 
summarized in Table III. 
IgM  anti-F9  antibodies  reacted  strongly with  embryos  throughout  their  entire 
preimplantation development. Negative controls were run using IgM anti-F9 anti- 
bodies absorbed with F9 cells. These did not stain the embryos, irrespective of their 
developmental  stage.  Unabsorbed  IgM  antibodies,  however,  strongly  stained  the 
unfertilized ovocytes at  the  1/64  dilution. The staining of embryos persisted until 
they reached the late morula stage. Later in development, trophectoderm cells had 
much less affinity for IgM anti-F9 antibodies, whereas inner cell mass cells retained 
the capacity to bind anti-F9 IgM. 
IgG1  anti-F9 antibodies were never found to react with any cell at any stage, at 
any dilution of the reagent (lowest 1/2.5). 
IgG2a,b anti-F9 antibodies, diluted  1/6, did not detect specific antigens on very 
early (one and two cell stages) preimplantation embryos. Between two and four cell 
stages, however, receptors begin to be expressed, which peak at the morula stage and 
disappear upon blastocyst formation. At this stage, these receptors are not detectable 
on trophectoderm cells or inner cell mass cells. 
Earlier  studies  dealing with  the  expression  of F9  antigens  on  preimplantation 
TAnLE III 
Activity of lgM, IgG1, and IgG2a,  b Anti-F9 Antibodies on Preimplantation Embryos 
Four-cell  Blastocyst 
Nonfertil-  One-cell  Two-cell  Antibodies  stage and 
ized egg  stage  stage  morulae  Trophecto-  Inner cell 
derm  mass 
IgM, diluted  1/64  ++*  +++  +++  +++  Traces  ++ 
27  8  14  24  4  18 
IgG1, diluted 1/2.5  NT:~  NT  0  0  0  0 
6  8  8  4 
IgG2, diluted  1/6  0  0  Traces, +  ++  Traces  0 
6  9  5  10  41  9  17 
* Upper line, intensity of staining; lower line, number of embryos tested. 
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embryos have been made using PYS-2 absorbed anti-F9 serum  (1,  7).  According to 
the results obtained with this reagent, F9 antigens were not detectable on unfertilized 
ovocytes, but did appear later, some 12 h  after fertilization. Consequently, IgM and 
IgG2a,b anti-F9 antibodies were absorbed on PYS-2 cells before being applied onto 
preimplantation  embryos.  The  pattern  of expression  of receptors  to  anti  IgG2a,b 
antibodies was left unchanged. By contrast, unfertilized ovocytes and one-cell embryos 
did not react any longer with IgM anti-F9 antibodies. ~Receptors to these specific IgM 
appeared  between  one  and  two  cell  stages.  Later  expression  was  unchanged  as 
compared with  the  one observed with  unabsorbed  IgM  antibodies.  Absorption  of 
anti-F9 IgG2a,b antibodies with mesodermal derivatives did not result in any signif- 
icant change of their activity on morulae. 
Discussion 
When  the  results  reported  above are summed up,  it  becomes apparent  that  the 
antigenic  determinants  detected  by  IgM,  IgG1,  and  IgG2a,b  antibodies  are  not 
identical;  the  anti-F9  serum  allows  the  detection  of at  least  three  independently 
expressed antigenic determinants whether or not borne by the same molecule. 
When one considers the expression of the three antigens separately, several conclu- 
sions can be reached.  (a) The IgM anti-F9 antibody receptors are detectable on most 
cells displaying E.C. features, whether they are derived from spontaneous or induced 
murine teratocarcinomas of various genetic origins, or from human testicular tumors. 
They are also detected easily on preimplantation embryos. These receptors are scarcely 
found on differentiated cell lines. Absorption experiments carried out on total anti-F9 
serum or on isolated anti-F9  IgM led to the conclusion that  two types of antigenic 
determinants  react  with  these  IgM;  one  is  found  on  E.C.  cells,  PYS-2,  and  on 
unfertilized ovocytes. The interaction between these IgM and their receptors does not 
cause a significant lysis of F9 cells. The other class of IgM receptors is found on E.C. 
cells and fertilized embryos only, and is detectable after absorption of anti-F9 IgM 
with  PYS-2  cells.  Therefore,  this  last  antigen  appears to be characteristic  of early 
embryonic cells and of their tumoral counterpart.  (b) The receptors to IgG 1 anti-F9 
antibodies are found on some E.C. lines and also~  on several differentiated cell types, 
all  of them  mesodermal derivatives.  Absorption  of these  antibodies  with  PCD2,  a 
myoblastic line, however, did not result in any significant change of their activities on 
F9 cells. It might, therefore, be concluded that the cross-reacting antigen common to 
F9 cells and the mesodermal derivatives tested is a minor component of the receptors 
to IgG1 displayed at the surface of F9 cells. IgG1 anti-F9 antibody receptors are not 
detected on preimplantation embryos. They are not merely associated with in vitro 
growth of cells because they have been detected at the surface of F9 cells growing as 
solid tumors, and the animals harboring these tumors were found to produce IgG1 
anti-F9 antibodies  (5).  Receptors to IgG1 antibodies might be related to cell surface 
antigens  common  to  E.C.  cells,  and  various  tumoral  and  transformed  cell  types 
identified by other authors  (28-30).  (c) The receptors to IgG2a,b anti-F9 antibodies 
are expressed on cultured cells (E.C. or differentiated derivatives) much the same way 
as IgG1 receptors. Again, absorption of IgG2a,b antibodies with PCD2 cells did not 
result  in  any  significant  decrease  of their  activity  when  tested  back  on  F9  cells. 
IgG2a,b receptors, however, are clearly distinguished  by their pattern of expression 
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It may be pointed out  that  F9 antigens recovered after precipitation  of E.C. cell 
extracts with anti-F9  serum  (and especially with  anti-F9  IgM antibodies,  data  not 
shown)  contain  long saccharidic  chains  characteristic of early embryonic cells  (31). 
On  the  other  hand,  the  main  target  of IgM  anti-F9  antibodies  have been  shown 
recently to be saccharidic residues (32). The absence of polymorphism of F9 antigens, 
which has been observed so far among various mouse inbred su:ains as well as among 
mammalian  species  (4),  might  thus  reflect  the  preservation  of these  saccharidic 
structures. 
Moreover, F9 antigens have been found to bear some relationship with t wa2 and t "5 
haplotypes of the T  locus  (7,  33).  This conclusion  has been  drawn  from studies  in 
which IgM receptors were looked at predominantly. One might then speculate that 
the cell surface components altered in t wa2 and t w5 homozygotes are saccharidic chains; 
some  products  of the  T  locus  would,  thus,  be  somehow  related  to  carbohydrate 
metabolism of the embryos, a  contention  supported by recent evidence brought by 
Cheng and Bennett  (34). 
Summary 
Using  an  affinity  chromatography  technique,  IgM,  IgG1,  and  IgG2a,b  anti-F9 
antibodies  have  been  isolated  from  the  anti-F9  serum;  their  activities  have  been 
analyzed by IF test on a variety of cell types, teratocarcinoma-derived cell lines, and 
embryos.  The  anti-F9  antibodies  react  with  at  least  three  independent  antigenic 
determinants not expressed on the same cell types, and that appear along different 
time-course during embryonic development. 
We thank Dr. M. Stanislawski  for his help in the serotyping of specific antibodies. 
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